Jeffrey Brady, MD
Urology · Orlando, FLNPI 1932195617
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $130,593 of the $144,676 with a category attached, or 90.3%. Boston Scientific accounts for 95.6% of it on its own, with 12 other manufacturers making up the rest. Among urology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 210 payments — averaging $688.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$138K
- Endo Pharmaceuticals Inc.$4K
- Coloplast$1K
- Endo USA, Inc.$583
- Astellas Pharma US Inc$125
- Johnson & Johnson$118
- plus $291 from 7 others
Across 5 payments — averaging $3884.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$19K
What the payments were for
- Consulting fees$2,4652%
- Speaking & faculty fees$130,59390%
- Travel & lodging$5,4634%
- Food & beverage$5,9904%
- Education$1650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 143 | $138,363 |
| Endo Pharmaceuticals Inc. | 17 | $4,115 |
| Coloplast | 32 | $1,081 |
| Endo USA, Inc. | 6 | $583 |
| Astellas Pharma US Inc | 3 | $125 |
| Johnson & Johnson | 1 | $118 |
| Pacira Pharmaceuticals Incorporated | 1 | $110 |
| Antares Pharma, Inc. | 1 | $50 |
| Myriad Genetic Laboratories, Inc. | 2 | $45 |
| Medtronic | 1 | $28 |
| AbbVie | 1 | $24 |
| 180 Medical, Inc. | 1 | $21 |
| Olympus America Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AdVance XP$86,557
- TACTRA$14,000
- XIAFLEX$3,777
- AMS 700$3,148
- ADVANCE$1,800
- AMS$1,000
- TITAN$258
- PENILE & TESTICULAR RECONSTRUCTN$124
- GENERAL ERECTILE DYSFUNCTION$119
- Erleada$118
- Luja Coude$110
- EXPAREL$110
- GENERAL KIDNEY STONE DISEASE$106
How this compares
$144,676 in reported general payments places this provider in the 95th percentile of 935 urology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 53 | $38,255 |
| Mirabegron ErMirabegron | 15 | $5,235 |
| Tolterodine Tartrate ErTolterodine Tartrate | 31 | $4,941 |
| Tamsulosin Hcl | 116 | $1,395 |
| Finasteride | 79 | $1,097 |
| Oxybutynin Chloride ErOxybutynin Chloride | 35 | $1,055 |
| Trospium Chloride ErTrospium Chloride | 11 | $946 |
| Clobetasol EmollientClobetasol Propionate/Emoll | 15 | $795 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 28 | $553 |
| Oxybutynin Chloride | 112 | $514 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 16 | $507 |
| Testosterone Cypionate | 11 | $476 |
| Gabapentin | 49 | $443 |
| Testosterone | 11 | $430 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 89 | $308 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $125 | $38,25553 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 935 urology providers in Florida.
Other urology in Orlando
- Olubayo TojuolaOrlando$283K
- Lucas WiegandOrlando$136K
- Christopher RussellOrlando$84K
- Albert OngOrlando$77K
- Paul PeritoCoral Gables$3.6M
- Scott SellingerTallahassee$2.3M
- Mark Anthony GonzalgoMiami$1M
- Edward GheilerHialeah$655K
- Rolando RiveraNaples$437K
- Matthew ErcolaniVenice$416K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.